Plus Therapeutics Inc Company Overview and Analyst Insights

Plus Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing treatments for central nervous system (CNS) disorders.

The company's pipeline includes a proprietary formulation of bevonol, a non-opioid analgesic, which has shown promise in treating various CNS-related conditions.

Plus Therapeutics has a strong leadership team, with CEO Brian Leedman bringing over 20 years of experience in the pharmaceutical industry to the table.

The company's innovative approach to CNS drug development has garnered attention from industry analysts, who are closely monitoring its progress.

Plus Therapeutics reported a net income of $5.2 million in Q2 2025, a significant improvement from the net loss of $2.9 million in Q2 2024.

The company's cash position has strengthened to $6.9 million as of June 30, 2025.

This is a notable achievement, indicating that Plus Therapeutics is on a solid financial footing.

The company's financial performance is a direct result of its successful CNS cancer treatment programs, which have shown significant progress in Q2 2025.

Plus Therapeutics has also completed the restructuring of its $15 million equity financing and received a $1.6 million CPRIT grant payment, further boosting its financial stability.

Take a look at this: Proargi 9

Plus Therapeutics has received a range of price target adjustments from analysts. HC Wainwright has adjusted its price target on the company to $8 from $3.50, while maintaining a Buy rating.

Maxim has also weighed in, adjusting its price target to $12 from $30, but keeping a Buy rating. This suggests that some analysts are optimistic about the company's future prospects.

Here are the specific price target adjustments from analysts:

Valuation Measures play a crucial role in determining a company's worth. They help investors and analysts understand the company's value relative to its peers.

Market capitalization, or Market Cap, is a key valuation metric. In this case, the Market Cap is 61.26M.

Enterprise Value, another important metric, is 54.41M. This figure takes into account the company's debt and cash on hand.

The Trailing P/E ratio is not available for this company. The Forward P/E ratio is also not provided.

The PEG Ratio, which is the Price-to-Earnings Growth Ratio, is not available for a 5-year expected period. This ratio helps investors evaluate a company's stock price relative to its earnings growth.

Readers also liked: Huntington Bancshares Earnings Call

The Price-to-Sales ratio is not available for the trailing 12-month period. This ratio helps investors compare a company's stock price to its revenue.

The Price-to-Book ratio is 20.19, which is based on the company's market price per share divided by its book value per share. This ratio can indicate whether a company's stock price is overvalued or undervalued.

Here are the Valuation Measures listed for reference:

Analysts' recommendations can be a valuable tool for investors looking to make informed decisions. HC Wainwright has adjusted its price target on Plus Therapeutics to $8 from $3.50, while maintaining a Buy rating.

Maxim has also weighed in on Plus Therapeutics, adjusting its price target to $12 from $30, and keeping a Buy rating. This suggests that analysts are optimistic about the company's future prospects.

JonesTrading has a more conservative view, starting Plus Therapeutics at Buy with a $5 price target. This is a lower target than some of the other analysts, but still indicates a positive outlook.

Broaden your view: Buy Magic Band

HC Wainwright has also adjusted Plus Therapeutics' price target to $3.50 from $7, while keeping a Buy rating. This is a decrease in the target, but the Buy rating suggests that the analyst still believes in the company's potential.

Here's a summary of the analysts' recommendations:

As you can see, the analysts' recommendations are varied, but most are optimistic about Plus Therapeutics' future prospects.

Plus Therapeutics' financial health is a concern, with a profit margin of 0.00%. This means the company is not generating any profit from its sales.

The return on assets (ttm) is a staggering -74.05%, indicating that the company is actually losing money on its assets. This is a significant red flag.

Net income available to common shareholders is -19.03M, which is a huge negative number. This suggests that the company is deeply in the red.

Revenue for the latest quarter (ttm) is 5.32M, but it's not enough to turn the company's fortunes around.

Here's a summary of the key metrics:

Rhenium Nanoliposome is a key component of Plus Therapeutics' innovative approach to treating cancer. It's a targeted delivery system that uses rhenium-based nanoparticles to selectively release chemotherapy drugs directly into the tumor.

This targeted approach allows for higher concentrations of the drug to reach the tumor site, reducing the harm to surrounding healthy cells. The rhenium nanoliposome is designed to be more effective and less toxic than traditional chemotherapy methods.

By leveraging the unique properties of rhenium, Plus Therapeutics is able to create a more precise and controlled delivery system that holds promise for improving treatment outcomes for cancer patients.

Rhenium Nanoliposome is a type of nanoliposome that incorporates rhenium into its structure.

Rhenium is a rare and highly valued metal that has unique properties, making it an excellent choice for use in nanoliposomes.

These nanoliposomes are designed to be extremely small, measuring around 100-200 nanometers in diameter.

This small size allows them to easily pass through cell membranes, making them ideal for targeted drug delivery.

Rhenium's high density and atomic number also make it an effective contrast agent for medical imaging.

In fact, rhenium-based nanoliposomes have been shown to improve the accuracy of imaging techniques such as MRI and CT scans.

The use of rhenium in nanoliposomes has also been found to enhance their stability and shelf life.

This is due in part to rhenium's ability to form strong bonds with other molecules, making the nanoliposomes more resistant to degradation.

Researchers have also been exploring the potential of rhenium nanoliposomes for use in cancer treatment.

Studies have shown that these nanoliposomes can selectively target cancer cells, reducing the harm to healthy cells and improving treatment outcomes.

In the world of biotechnology and medical research, exciting developments are happening. UnitedHealth Unit has signed a national coverage deal with CNSide Diagnostics for a tumor cell lab test.

This deal is a significant step forward in making advanced medical testing more accessible to patients. The test is designed to help doctors diagnose and treat cancer more effectively.

Cancer research is a top priority, and companies like Plus Therapeutics are working hard to make a difference. They've recently announced an additional $1.9 million advance payment from CPRIT.

This funding will help Plus Therapeutics continue their research and bring new treatments to patients who need them.

Plus Therapeutics is actively involved in clinical trials to develop innovative treatments for CNS cancers. The company has a Phase 1 clinical trial planned for 2025, ReSPECT-PBC, to treat rare and aggressive pediatric brain and spinal cord tumors.

Cancer is the leading cause of death by disease among children in the U.S., with brain and spinal cord tumors accounting for 26% of childhood cancers. Ependymoma is a rare type of tumor that forms in ependymal cells lining the brain and spinal cord.

Plus Therapeutics has successfully completed the ReSPECT-LM Phase 1 trial for REYOBIQ in treating leptomeningeal metastases. The trial demonstrated significant efficacy with a 76% radiographic and 87% clinical response rate through day 112.

The ReSPECT-PBC Clinical Trial is a U.S. Phase 1 Clinical Trial planned to initiate in 2025 for pediatric brain cancer treatment.

Cancer is the leading cause of death by disease among children in the U.S.

Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Ependymoma is a rare, slow- or fast-growing primary CNS tumor that forms in ependymal cells.

This type of tumor may spread throughout the CNS but spread outside of the CNS is rare.

All ependymomas can recur, but often patients are tumor-free for years before testing shows new tumor growth.

Plus Therapeutics has made a significant breakthrough in treating leptomeningeal metastases with its Reyo biq treatment. The company announced positive results from its ReSPECT-LM Phase 1 trial, which demonstrated a 76% radiographic and 87% clinical response rate through day 112.

The trial involved 29 subjects across 6 cohorts and showed a 100% reduction in CSF tumor cells at day 28. This is a promising outcome, as five of seven patients who achieved this level of tumor cell reduction are still alive after at least one year.

The median overall survival in the trial reached 9 months, which is substantially better than the typical 4-month survival rate for patients with leptomeningeal metastases. This improvement in survival rate is a significant step forward in the treatment of this condition.

A recommended Phase 2 single dose of 44.1 mCi has been established, with no dose-limiting toxicities in cohorts 1-4 and a manageable safety profile in higher doses. This suggests that Reyo biq has a favorable safety profile, which is an important consideration for patients and healthcare providers.

The CNSide diagnostic platform has been making waves in the medical community, and for good reason. It's designed to identify tumor cells that have metastasized to the central nervous system.

With an impressive 92% sensitivity and 95% specificity, this diagnostic tool is a game-changer for cancer patients. Its ability to accurately detect cancer cells in the brain and spinal cord has been validated through over 11,000 tests performed at more than 200 U.S. cancer institutions since 2020.

The CNSide platform has already influenced treatment decisions in over 90% of cases, giving doctors and patients valuable information to make informed decisions about care.

Plus Therapeutics has regained compliance with Nasdaq listing requirements. This is a significant achievement for the company, which has worked hard to meet the necessary criteria.

The company received confirmation from Nasdaq on August 22, 2025, that it meets two key requirements: maintaining a market value of listed securities above $35 million and stockholders' equity exceeding $2.5 million.

As a result of regaining compliance, Plus Therapeutics has been granted an extended grace period until November 12, 2025, to meet the $1.00 bid price requirement. This replaces the previous September 8 deadline, giving the company more time to meet this important milestone.

The company remains under panel monitoring for the Equity Standard through August 22, 2026. This means that Plus Therapeutics will continue to be closely watched by Nasdaq to ensure it meets the necessary requirements.

Plus Therapeutics' subsidiary, CNSide Diagnostics, has received CMS accreditation for its Houston-based laboratory.

This accreditation confirms compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations for testing human specimens.

CNSide Diagnostics' accreditation is a crucial milestone for the broader market release of the CNSide cerebrospinal fluid (CSF) assay platform, designed for patients with or at risk for CNS cancers.

The accreditation enables state licensure in 48 states, broad commercial insurance coverage, access to government payor coverage, and expansion of payment coding opportunities.

By achieving this accreditation, Plus Therapeutics has taken a significant step towards making its CNSide platform more accessible to patients across the country.

Access to premium industry data and analytics can be a game-changer for businesses, allowing them to remove risk and uncertainty and gain a competitive edge.

With Plus Therapeutics' industry data and analytics, you can secure actionable leads and make informed decisions.

Removing risk and uncertainty is crucial for any business, and with the right tools, you can achieve this and stay ahead of the competition.

Plus Therapeutics offers access to company-related investigative journalist content, which can be a valuable resource for those seeking to stay informed about industry trends and developments.

This can be especially useful for businesses looking to expand their reach and stay competitive in a rapidly changing market.

By leveraging Plus Therapeutics' industry data and analytics, you can gain a deeper understanding of the market and make more informed decisions about your business.

Plus Therapeutics received an additional $1.9 million advance payment from CPRIT.

This payment was announced on September 22, just three days after the company announced a national coverage agreement with UnitedHealthcare Insurance Company for its CNSide Cerebrospinal Fluid Assay.

The payment is a significant boost to the company's finances and demonstrates the growing trust in their work by major institutions.

Plus Therapeutics continues to make strides in the field of cancer treatment, and this payment is just one example of their progress.

Here's a breakdown of the company's recent announcements:

These announcements demonstrate the company's commitment to advancing cancer treatment and its growing recognition by major institutions.

Plus Therapeutics has a Catalyst Calendar that allows you to proactively evaluate the company's catalyst impacts, giving you a competitive edge and improving corporate planning.

Staying ahead of the competition is crucial, and Plus Therapeutics' Catalyst Calendar is a valuable tool for achieving this goal.

Bolstering business development with timely opportunities is also a key benefit of the Catalyst Calendar, enabling you to make the most of emerging trends and market shifts.

On a similar theme: Catalyst Pharmaceuticals

Plus Therapeutics is part of a competitive landscape that includes several notable players. The company is headquartered in the United States of America, specifically in Austin, Texas.

Let's take a closer look at the competitors listed. Plus Therapeutics has a relatively small workforce, with just 21 employees. In contrast, Bayer AG has a massive workforce of 92,815 employees, with headquarters in Leverkusen, Germany.

The size difference is striking, but it's worth noting that Plus Therapeutics is a public company, just like Bayer AG. This suggests that Plus Therapeutics has a strong presence in the market, despite its smaller size.

Here's a brief overview of the competitors' key parameters:

Plus Therapeutics operates in a global market, alongside competitors with significant resources and presence.